jondoeuk's latest activity

Unlike oral finasteride or dutasteride, which reduce systemic DHT levels, pyrilutamide is designed to work locally with a different...

It is critical to distinguish between a drug losing all efficacy and a drug peaking and stabilising. According to top-line data from...

Yes. (2026-03-18) ''In terms of efficacy: compared to the placebo group, both 1.0% BID (i.e. twice a day) group and 0.5% BID group...

New PP405 Phase 2/3 https://clinicaltrials.gov/study/NCT07819435 Estimated start date of Sept 2026. Primary completion date of Dec...

You brought up ''drug resistance'' and all I said was that in individuals who have exceptionally high systemic or localised scalp DHT...

The second phase III clinical trial was successful. Per Kintor, pyrilutamide has entered the new drug application stage in China. If...

Yes. In preclinical binding assays, pyrilutamide demonstrates significantly higher potency than other prominent androgen receptor...

RU58841 has no published clinical safety or efficacy data in humans. Because both RU58841 and pyrilutamide are competitive blockers...

The half-life is approximately 6–8 hours.

The numbers show statistically significant and clinically meaningful hair growth outcomes, while demonstrating excellent safety. A total...

Triple Hair (Canada) began Phase 3 clinical trials for its Therapy-07 (THO7) topical in Vancouver, Canada, It contains minoxidil...

See my reply to coco_304

Pyrilutamide (KX-826) is sold directly to consumers as a cosmetic under the brand name Koshine ahead of completing approval. You can buy...

Per Kintor's latest pipeline page modification, pyrilutamide has entered the new drug application stage in China. If the application is...

Kintor plans to initiate the phase IIb/III clinical trial of GT20029 for male androgenetic alopecia in China this year.